116 EYE AREA CARE


AI-designed peptide for eye contour rejuvenation


Consuelo Garcia-Hernandez, Ramón Subirós, Mauricio Valerio-Santiago, Cristina Bonell, Gemma Mola, Albert Soley, Raquel Delgado – Lubrizol


ABSTRACT


The skin surrounding the eyes is anatomically and functionally distinct from other facial areas. It is thin, continuously exposed to repeated mechanical stress from blinking and facial expression, and supported by a delicate arrangement of blood vessels, lymphatic vessels, epidermal and dermal layers, adipose compartments, muscles and retaining connective tissues. Due to this complexity, relatively small biological changes may rapidly become visible as signs of tiredness or ageing.1,2 Consumers rarely experience a single eye


contour concern in isolation. Dark circles frequently coexist with puffiness, while eye bags are often accompanied by wrinkles, skin laxity and a loss of firmness. Droopy eyelids are commonly associated with age-related weakening of supporting soft tissues, particularly periocular musculature and connective structures. These observations suggest that periocular


ageing should not be viewed as a collection of independent concerns, but rather as the visible consequence of a complex and interconnected biological process involving multiple tissue compartments.1,2 Traditional cosmetic strategies often target


individual visible concerns despite the biological interdependence of the tissues that collectively define eye contour architecture. A more integrated view considers the periocular


area as a microenvironment maintained by seven soft tissues: the vascular system, lymphatic system, epidermis, dermis, adipose tissue, muscle and


PERSONAL CARE MAGAZINE October 2026


ligament-support structures. The vascular and lymphatic systems regulate


fluid exchange and clearance; the epidermis contributes barrier function and pigmentation balance; the dermis provides extracellular matrix support; adipose tissue influences tissue volume; muscle controls eye opening and eyelid position; and ligament structures help maintain tissue anchoring and three-dimensional support.1,2 PAR-1 is a relevant upstream regulator because


endothelial permeability connects vascular and lymphatic dysfunction with several visible periocular concerns. Beyond its effects on barrier function, PAR-1 activation triggers pro-inflammatory signalling pathways, including NF-κB activation, promoting the production of inflammatory mediators and contributing to the maintenance of a chronic low- grade inflammatory state. When endothelial cohesion is altered, fluids,


cytokines, metabolites and haemoglobin-derived compounds can accumulate in surrounding tissues. This microenvironmental ‘flooding’ amplifies inflammation, pigmentation changes, extracellular matrix degradation and tissue swelling. As a result, progressive deterioration of periocular soft tissues may fuel a self-amplifying cycle of tissue dysfunction and visible ageing.3 This integrated view is summarized in the Amplifying Release Cycle (Figure 1), which links PAR-1 activation with increased vascular and lymphatic permeability, leakage of biological mediators into the eye contour microenvironment,


The eye contour is one of the most complex anatomical regions of the face and among the first to exhibit visible signs of ageing. Dark circles, eye bags, wrinkles, skin laxity, droopy eyelids and signs of fatigue are commonly addressed as separate cosmetic concerns. However, growing evidence suggests that these manifestations are interconnected and arise from alterations affecting multiple soft tissues within the periocular microenvironment. Recent advances in AI-assisted molecular discovery have enabled the identification of novel cosmetic peptides capable of targeting key biological pathways involved in tissue homeostasis. This article describes the discovery and characterization of an AI- designed peptide developed to modulate endothelial permeability through protease- activated receptor 1 (PAR-1), a central regulator of vascular and lymphatic barrier function. Mechanistic studies demonstrated activity across seven periocular soft tissues: vascular system, lymphatic system, epidermis, dermis, adipose tissue, muscle and ligament tissues. The AI-designed peptide reduced endothelial permeability, reinforced epidermal barrier markers, decreased melanin accumulation, enhanced extracellular matrix proteins, reduced lipid accumulation in adipocytes, increased active mitochondria and IGF-1 in aged muscle models, and restored structural markers in aged ligament cells. Clinical evaluation in a multicentric, placebo-controlled, half-face study further supported visible improvements in multiple eye contour parameters. Collectively, these data support a new framework for holistic periocular care: seven soft tissues, one eye contour


and progressive stress on surrounding soft tissues. In this context, a multifunctional active


capable of influencing more than one tissue compartment may provide a more relevant strategy for comprehensive eye contour rejuvenation. The objective of this article is to present a scientific overview of Eyeseryl® All-In peptide, an AI- designed peptide developed to target a central biological driver of periocular microenvironment


www.personalcaremagazine.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132